Citations

Clear

410 citation(s) found for "Shu, Yu".

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
Khan, Aliya , Rubin, Mishaela R. , Vokes, Tamara , Shoback, Dolores , Abbott, Lisa G, Kohlmeier, Lynn, Phil, Susanne, An, Xuebei, Lai, Bryant, Ukena, Jenny, Clarke, B.L. , Schwarz, Peter , Gagnon, Claudia , Palermo, Andrea , Hofbauer, Lorenz C. , Cetani, Filomena , Smith, Alden Raymond , Le, John, Sibley, Chris G. , Shu, Aimee D , Rejnmark, Lars

Mayo Clinic

Journal of the Endocrine Society | October 5, 2023 | Volume: 7 | Issue: Supplement_1 | Pages: No page available

10.1210/jendso/bvad114.563 Get It

Abstract Disclosure: B. Clarke: Advisory Board Member; Self; Ascendis Pharma, Takeda, Entera-Bio, Extend-Bio, Amolyt. Consulting Fee; Self; Ascendis Pharma, Takeda, Entera-Bio, Extend-Bio, Amolyt. Grant Recipient; Self; Ascendis Pharma, Takeda. Research Investigator; Self; Ascendis Pharma, Takeda. Other; Self; Ascendis Pharma, Takeda, Entera-Bio, Extend-Bio, Amolyt. A.A. Khan: Advisory Board Member; Self; Amgen Inc, Alexion Pharmaceuticals, Inc., Ascendis Pharma, Takeda, Ultragenyx. Consulting Fee; Self; Amgen Inc, Alexion Pharmaceuticals, Inc., Amolyt, Ascendis Pharma, Ultragenyx. Grant Recipient; Self; Amolyt. Research Investigator; Self; Radius Health, Inc, Takeda, Ultragenyx, Amolyt, Ascendis Pharma, Chugai. Speaker; Self; Amgen Inc. Other; Self; Amgen Inc, Alexion Pharmaceuticals, Inc., Ascendis Pharma, Takeda, Ultragenyx. M.R. Rubin: Research Investigator; Self; Chugai Pharma. P.E. Schwarz: Stock Owner; Self; Novo Nordisk, Genmab. T.J. Vokes: Consulting Fee; Self; Takeda, Ascendis Pharma. Research Investigator; Self; Ascendis Pharma, Radius Health, Inc. D.M. Shoback: Research Investigator; Self; Bone Health Tech. C. Gagnon: Advisory Board Member; Self; Novo Nordisk. Grant Recipient; Self; Shire, Takeda, Ascendis Pharma. Research Investigator; Self; Novo Nordisk. Other; Self; Amgen Inc. A. Palermo: Consulting Fee; Self; Theramex, Bruno, Farmaceutici, Amgen Inc. Grant Recipient; Self; Amgen Inc. Research Investigator; Self; Amgen Inc, Shire, Ascendis Pharma. Speaker; Self; UCB, Amgen Inc. L.G. Abbott: Advisory Board Member; Self; Ascendis. Research Investigator; Self; Takeda, Shire, Ascendis Pharma. Speaker; Self; Abbott Laboratories, Clarus. Other; Self; Ascendis. L.C. Hofbauer: Advisory Board Member; Self; Amgen Inc, UCB. Other; Self; Amgen Inc, UCB. L. Kohlmeier: Advisory Board Member; Self; Alexion Pharmaceuticals, Inc., Ascendis Pharma. Research Investigator; Self; Ascendis Pharma. Speaker; Self; Amgen Inc, Radius Health, Inc, Alexion Pharmaceuticals, Inc., Ascendis Pharma. Other; Self; Amgen Inc, Radius Health, Inc, Alexion Pharmaceuticals, Inc., Ascendis Pharma, MediMaps. F. Cetani: None. S. Phil: Employee; Self; Ascendis Pharma. X. An: Employee; Self; Ascendis Pharma. A.R. Smith: Employee; Self; Ascendis Pharma. B. Lai: Employee; Self; Ascendis Pharma. J. Le: Employee; Self; Ascendis Pharma. J. Ukena: Employee; Self; Ascendis Pharma. C. Sibley: Employee; Self; Ascendis Pharma. A. Shu: Employee; Self; Ascendis Pharma. L. Rejnmark: Advisory Board Member; Self; Takeda, Amolyt. Research Investigator; Self; Takeda, Kyowa Kirin International, Ascendis Pharma, Calcilytix Therapeutics. Other; Self; Calcilytix Therapeutics. Objective: Evaluate the long-term efficacy and safety of TransCon PTH as a potential hormone replacement therapy for hypoparathyroidism. Methods: PaTHway is a phase 3 trial of TransCon PTH with a placebo (PBO)-controlled 26-week blinded period and a 156-week open-label extension (OLE) period. Results through Week 52 (26 weeks blinded + 26 weeks OLE) are reported. Three-component efficacy endpoint: normal serum calcium (8.3-10.6 mg/dL) and independence from conventional therapy (≤600 mg/day of elemental calcium and no active vitamin D). Other endpoints: Hypoparathyroidism Patient Experience Scale (HPES); 36-Item Short Form Survey (SF-36); bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA); bone turnover markers (BTM) procollagen type 1 N-terminal propeptide (P1NP) and C-terminal telopeptide of type 1 collagen (CTx). Safety was assessed by 24-hour urine calcium and reported treatment-emergent adverse events (TEAEs). Results: Of the 82 participants given study drug, 79 completed blinded treatment and entered the OLE, and 78 (59 TransCon PTH/TransCon PTH, 19 PBO/TransCon PTH) completed Week 52. Overall at Week 52, 81% (63/78) met the efficacy endpoint, 95% (74/78) achieved independence from conventional therapy, and none required active vitamin D. Mean albumin-adjusted serum calcium was within the normal range at all time points in the OLE (8.9 mg/dL at Week 52). Mean Week 52 HPES scores showed sustained improvement from baseline in disease-related symptoms and the impact of hypoparathyroidism on physical functioning and daily life. Mean Week 52 SF-36 physical functioning scores also remained above baseline. In the TransCon PTH/TransCon PTH group, mean BMD corrected Z-scores trended toward norms from baseline to Weeks 26 and 52:1.5, 0.7, 0.7 at the lumbar spine (L1-L4); 0.8, 0.3, 0.3 at femoral neck; 0.9, 0.5, 0.4 at total hip; and 0.3, 0.3, 0.3 at distal 1/3 radius; P1NP peaked at Week 26 and CTx at Week 12. Smaller incremental changes were seen in BMD and BTM from Weeks 26 to 52 than baseline to Week 26. In the PBO/TransCon PTH group, changes in BMD and BTM from Week 26 to 52 resembled those in the TransCon PTH/TransCon PTH group from baseline to Week 26. Mean 24-hour urine calcium excretion decreased from 376 mg/day at baseline to 195 mg/day at Week 52. Most TEAEs were mild or moderate and none led to discontinuation of the study drug or trial. Conclusions: At Week 52 of the PaTHway trial, TransCon PTH showed a similar sustained efficacy, safety, and tolerability profile to that of Week 26, demonstrating its potential as a hormone replacement therapy for adults with hypoparathyroidism. Indices of skeletal dynamics trended toward age- and sex-matched norms in the TransCon/TransCon PTH group. TransCon PTH treatment in the PBO/TransCon PTH group showed rapid improvement in all outcomes in the first 26 weeks of the OLE consistent with the pattern in the TransCon PTH group during the blinded period. Presentation: Saturday, June 17, 2023
Locally Low-Rank Denoising of Multi-Echo Functional MRI Data With Application in Resting-State Analysis
Meyer, Nolan , Ahmed, Zaki , In, Myung‐Ho , Shu, Yunhong , Trzasko, Joshua D. , Meyer, Nolan K , In, Myung-Ho , Kang, Daehun , Huston, John , Bernstein, Matt A.

Mayo Clinic

Topics in Magnetic Resonance Imaging | October 5, 2023 | Volume: 32 | Issue: 5 | Pages: 37-49

10.1097/rmr.0000000000000307 | PMID 37796647 Get It

Abstract: Objectives: Locally low-rank (LLR) denoising of functional magnetic resonance imaging (fMRI) time series image data is extended to multi-echo (ME) data. The proposed method extends the capabilities of non-physiologic noise suppression beyond single-echo applications with a dedicated ME algorithm. Materials and Methods: Following an institutional review board (IRB) approved protocol, resting-state fMRI data were acquired in 7 healthy subjects. A compact 3T scanner enabled whole-brain acquisition of multiband ME fMRI data at high spatial resolution (1.4 × 1.4 × 2.8 mm3) with a 1810 ms repetition time (TR). Image data were denoised with ME-LLR preceding functional processing. The results of connectivity maps generated from denoised data were compared with maps generated with equivalent processing of non-denoised images. To assess ME-LLR as a method to reduce scan time, comparisons were made between maps computed from image data with full and retrospectively truncated durations. Assessments were completed with seed-based connectivity analyses using echo-combined image data. In a feasibility assessment, nondenoised and denoised full-duration echo-combined data were equivalently processed with independent component analysis (ICA) and compared. Results: ME-LLR denoising yielded strengthened resting-state network connectivity maps after nuisance regression and seed-based connectivity analysis. In assessing ME-LLR as a scan reduction mechanism, maps generated from denoised data at half scan time showed comparable quality with maps generated from full-duration, non-denoised data, at both single subject and group levels. ME-LLR substantially increased temporal signal-to-noise ratio (tSNR) for image data respective to each individual echo and for image data after nuisance regression. Among echo-specific image volumes, increases in tSNR yielded by ME-LLR were most pronounced for image data with the longest echo time and thereby lowest SNR. ICA showed resting-state networks consistently identified between non-denoised and denoised data, with clearer demarcation of networks for ME-LLR. Conclusions: ME-LLR is demonstrated to suppress non-physiologic noise, enhance functional connectivity map quality, and could potentially facilitate scan time reduction in ME-fMRI.
A Likelihood Ratio Approach for Utilizing Case-Control Data in the Clinical Classification of Rare Sequence Variants: Application to BRCA1 and BRCA2
Zanti, Maria , O'Mahony, Denise G , Li, Hongyan , Aittomäkkiki, Kristiina, Andrulis, Irene L. , Aronson, Kristan J. , Bolla, Manjeet K. , Brenner, Hermann , Caputo, Sandrine M. , Chang‐Claude, Jenny , Collaborators, GC-HBOC study, Daly, Mary B., Nicolo, Arcangela De , Eccles, Diana M., Engel, Christoph , Evans, D. Gareth , Fasching, Peter A. , Giele, Willemina R. R. Geurts -, Glendon, Gord , Goldberg, Mark S. , Gómez, E. , Güendert, Melanie, Hahnen, Eric , Haiman, Christopher A. , Hamann, Ute, Harkness, Elaine F. , Hogervorst, Frans B.L., Hoppe, Reiner , Houdayer, Claude , Houlston, Richard S. , Howell, Anthony , Investigators, ABCTB, Jakimovska, Milena , John, Esther M. , Kristensen, Vessela N. , Lambrechts, Diether , Léone, Mélanie, Lindblom, Annika , Mannermaa, Arto, Manoochehri, Mehdi, Manoukian, Siranoush , Menon, Usha , Offit, Kenneth, Park, Sue K. , Peto, Julian , Plaseska‐Karanfilska, Dijana , Romero, Atocha , Schmutzler, Rita K. , Stone, Jennifer , Tapper, William , Teo, Soo‐Hwang , Thomassen, Mads , Vachon, Celine M. , Vega, Ana , Wang, Qin , Wappenschmidt, Barbara , Zheng, Wei , Easton, Douglas F. , Goldgar, David E., Eccles, Diana , Lambrechts, Diether , Houdayer, Claude , Lambrechts, Diether , Teo, Soo H , Eccles, Diana , Menon, Usha , Houlston, Richard S , Vega, Ana , Evans, D Gareth , John, Esther M , Lambrechts, Diether , Brenner, Hermann , Romero, Atocha , Engel, Christoph , Zheng, Wei , Stone, Jennifer , Gómez-García, Encarna B , De Nicolo, Arcangela , Manoukian, Siranoush , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Parsons, Michael T. , Dennis, Joe , Anton‐Culver, Hoda , Augustinsson, Annelie , Becher, Heiko , Bojesen, Stig E. , Brown, Melissa A. , Buys, Saundra S. , Canzian, Federico , Castelao, Jose E. , Czene, Kamila , Devilee, Peter , Dörk, Thilo , Dunning, Alison M. , Dwek, Miriam , Gago-Domínguez, Manuela , García‐Closas, Montserrat , García-Sáenz, José Á. , Gentry‐Maharaj, Aleksandra , Geurts-Giele, Willemina R.R. , Giles, Graham G. , Guénel, Pascal , Hall, Per N , Hollestelle, Antoinette , Hopper, John L. , Jakubowska, Anna , Jernström, Helena , Kaaks, Rudolf , Kitahara, Cari M. , Koutros, Stella , Kraft, Peter , Lacey, James V. , Léoné, Mélanie, Lubiński, Jan , Lush, Michael J. , Mannermaa, Arto, Margolin, Sara , Martı́nez, Marı́a Elena , Milne, Roger L. , Monteiro, Álvaro N.A. , Murphy, Rachel A. , Neuhausen, Susan L. , Nevanlinna, Heli , Newman, William G. , James, Paul A. , Peterlongo, Paolo , Punie, Kevin , Radice, Paolo , Rashid, Muhammad Usman , Rennert, Gad , Rosenberg, Efraim H. , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Shu, Xiao‐Ou , Simard, Jacques , Southey, Melissa C. , Stoppa‐Lyonnet, Dominique , Tamimi, Rulla M. , Taylor, Jack A. , Teras, Lauren R. , Terry, Mary Beth , Troester, Melissa A. , Vachon, Celine M. , Vreeswijk, Maaike P.G. , Weinberg, Clarice R. , Wolk, Alicja , Feng, Bing , Couch, Fergus J. , Spurdle, Amanda B. , Michailidou, Kyriaki

Mayo Clinic

Human Mutation | September 15, 2023 | Volume: 2023 | Issue: No issue available | Pages: 1-17

10.1155/2023/9961341 | PMID 38725546 Get It

A large number of variants identified through clinical genetic testing in disease susceptibility genes are of uncertain significance (VUS). Following the recommendations of the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP), the frequency in case-control datasets (PS4 criterion) can inform their interpretation. We present a novel case-control likelihood ratio-based method that incorporates gene-specific age-related penetrance. We demonstrate the utility of this method in the analysis of simulated and real datasets. In the analysis of simulated data, the likelihood ratio method was more powerful compared to other methods. Likelihood ratios were calculated for a case-control dataset of BRCA1 and BRCA2 variants from the Breast Cancer Association Consortium (BCAC) and compared with logistic regression results. A larger number of variants reached evidence in favor of pathogenicity, and a substantial number of variants had evidence against pathogenicity—findings that would not have been reached using other case-control analysis methods. Our novel method provides greater power to classify rare variants compared with classical case-control methods. As an initiative from the ENIGMA Analytical Working Group, we provide user-friendly scripts and preformatted Excel calculators for implementation of the method for rare variants in BRCA1, BRCA2, and other high-risk genes with known penetrance.
Introduction to concept inventories for medical physics education
Cetnar, Ashley J. , Besemer, Abby, Bry, Victoria, Buckey, C, Burmeister, Jay , Rodrigues, Anna , Schubert, Leah , Speidel, Michael A. , Sutlief, Steven , Yu, Amy S. , Buckey, Courtney R, Yu, Amy Shu-Jung , Bry, Victoria N.

Mayo Clinic

Journal of Applied Clinical Medical Physics | August 30, 2023 | Volume: 24 | Issue: 10 | Pages: No page available

10.1002/acm2.14130 | PMID 37646429 Get It

AbstractConcept inventories are multiple choice exams designed with the intention to test core concepts on specific subjects and evaluate common misconceptions. These tests serve as a useful tool in the classroom to assess value added by the instructor's educational methods and to better understand how students learn. They can provide educators with a method to evaluate their current teaching strategies and to make modifications that enhance student learning and ultimately elevate the quality of medical physics education. The use of concept inventories in introductory college physics courses revealed important gaps in conceptual understanding of physics by undergraduate students and motivated a shift of physics teaching towards more effective methods, such as active learning techniques. The goal of this review is to introduce medical physicists to concept inventories as educational evaluation tools and discuss potential applications to medical physics education by development through multi‐institutional collaboration.
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Ou, Fang‐Shu , Ahn, Daniel H. , Dixon, Jesse G. , Lou, Yiyue , Hubbard, Joleen M. , Goldberg, Richard M. , Hoff, Paulo M. , Douillard, Jean‐Yves , Hecht, J. Randolph , Hurwitz, Herbert I. , Punt, Cornelis J.A. , Koopman, Miriam , Bokemeyer, Carsten , Fuchs, Charles S. , Cremolini, Chiara , Kabbinavar, Fairooz F. , Bekaii‐Saab, Tanios , Chibaudel, Benoist , Zalcberg, John , Adams, Richard , Gramont, Aimery de , Shi, Qian , Kasi, Pashtoon Murtaza , Hubbard, Joleen , Goldberg, Richard M , Bokemeyer, Carsten , Zalcberg, John , Adams, Richard , Shi, Qian , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Cremolini, Chiara , Chibaudel, Benoist , Dixon, Jesse G , Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Schmoll, Hans‐Joachim , Venook, Alan P. , Díaz‐Rubio, Eduardo , Tebbutt, Niall C. , Yoshino, Takayuki

Mayo Clinic

Cancers | August 15, 2023 | Volume: 15 | Issue: 16 | Pages: 4117

10.3390/cancers15164117 | PMID 37627145 Get It

Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes.
Changes in Prescribing Patterns in Stage III Colon Cancer
Walden, Daniel J., Larson, Joseph J. , Kang, Sandra , Griswold, Cassia R. , Ueberroth, Benjamin E. , Patel, Bhamini, Draper, Amber , Raman, Puneet , Bekaii‐Saab, Tanios , Ahn, Daniel H. , Wu, Christina S., Bekaii-Saab, Tanios S , Griswold, Cassia , Ou, Fang‐Shu , Walden, Daniel J., Alese, Olatunji B. , Sonbol, Mohamad Bassam , Wu, Christina

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 841-850.e4

10.6004/jnccn.2023.7028 | PMID 37549913 Get It

Background: For patients with resected stage III colon cancer, 6 months of adjuvant fluoropyrimidine-based chemotherapy has been the standard of care. The IDEA collaboration aimed to evaluate whether 3 months of adjuvant chemotherapy was noninferior to 6 months. Despite failing to meet its primary endpoint, the subgroup analyses demonstrated noninferiority based on regimen and treatment duration when a risk-stratified approach was used. Patients and Methods: To evaluate the impact of the results of the IDEA collaboration, we evaluated adjuvant chemotherapy prescribing practice patterns, including planned adjuvant treatment regimen and duration from January 1, 2016, to January 31, 2021. The time period was selected to evaluate chemotherapy prescribing patterns prior to the abstract presentation of the IDEA collaboration in June 2017 and after full manuscript publication in March 2018. Results: A total of 399 patients with stage III colon cancer who received adjuvant chemotherapy were included in the analysis. A significant increasing trend for use of 3 months of adjuvant chemotherapy was observed after presentation of the IDEA abstract (P<.001). A significant change in CAPOX (capecitabine/oxaliplatin) prescribing was also observed, increasing from 14% of patients prior to presentation of the IDEA abstract to 48% after presentation (P<.001). Comparing 3 months of CAPOX with 6 months of FOLFOX (fluorouracil/leucovorin/oxaliplatin), 3 months of CAPOX use also steadily increased over time (adjusted odds ratio [aOR], 1.28; 95% CI, 1.20–1.37; P<.001). Among subgroups of interest, no differences in adoption of CAPOX were observed. The adoption of 3 months of CAPOX was similar in patients with low-risk cancer (aOR, 1.27; 95% CI, 1.17–1.37) and those with high-risk cancer (aOR, 1.31; 95% CI, 1.16–1.47). Conclusions: Despite the IDEA collaboration failing to demonstrate noninferiority of 3 months’ duration of adjuvant therapy compared with 6 months, the findings have influenced practice prescribing patterns, favoring CAPOX and a shorter duration of planned adjuvant treatment.
Prestroke and Poststroke Sulfonylurea Exposure and Functional Outcomes: A Post Hoc Analysis of the SHINE Trial
Shu, Liqi , Zhang, Wenyuan , Yaghi, Shadi , Grilli, Anais , Havenon, Adam de , Barrett, Kevin M. , Johnston, Karen C. , Goldstein, Eric , de Havenon, Adam H , Goldstein, Eric D , Yaghi, Shadi

Mayo Clinic

Stroke | July 14, 2023 | Volume: 54 | Issue: 9 | Pages: No page available

10.1161/strokeaha.123.043496 | PMID 37449423 Get It

Image-Decomposition-Enhanced Deep Learning for Detection of Rotor Cores in Cardiac Fibrillation
Shu, Yu , Smith, Tianqi Gao, Tolkacheva, Elena G. , Cheng, Changqing , Arunachalam, S P , Arunachalam, Shivaram P.

Mayo Clinic

IEEE Transactions on Biomedical Engineering | July 13, 2023 | Volume: 71 | Issue: 1 | Pages: 68-76

10.1109/tbme.2023.3292383 | PMID 37440380 Get It

Development of an online calculator for the prediction of seizure freedom following pediatric hemispherectomy using the Hemispherectomy Outcome Prediction Scale (HOPS)
Weil, Alexander G. , Dimentberg, Evan , Lewis, Evan , Ibrahim, George M. , Tseng, Chi‐Hong , Chen, Jia‐Shu , Lin, Kao‐Min, Cai, Lixin , Liu, Qingzhu , Lin, Jiuluan , Mathern, Gary W. , Smyth, Matthew D. , O’Neill, Brent R., Dudley, Roy , Ragheb, John , Bhatia, Sanjiv, Delev, Daniel , Zentner, Josef , Bollo, Robert J. , Issabekov, Galymzhan , Zhu, Hongwei , Connolly, Mary , Steinbok, Paul , Zhang, Kai , Weiner, Howard L. , Lapalme‐Remis, Samuel , Tripathi, Manjari , Chandra, P. Sarat , Hader, Walter , Wang, Feng‐Peng , Champagne, Pierre Olivier, Brunette‐Clément, Tristan , Budke, Marcelo , Pérez-Jiménez, María Ángeles, Raftopoulos, Christian , Finet, Patrice, Michel, Pauline, Schaller, Karl , Malone, Christian Cantillano, Pociecha, Juan , Chamorro, Noelia, Muro, Valeria L., Lehe, Marec von , Vieker, Silvia, Gaillard, William D. , Khateeb, Mashael Al, Alotaibi, Faisal , Krayenbühl, Niklaus , Bolton, Jeffrey , Chen, Jia-Shu , Zhou, Wen-Jing , Ramantani, Georgia , Dorfer, Christian , Feucht, Martha , Wong-Kisiel, Lily, Tripathi, Manjari , Sarat Chandra, Poodipedi , von Lehe, Marec , Pearl, Phillip L , Fallah, Aria , Gaillard, William D , Weil, Alexander G , Kola, Olivia , Ramantani, Georgia , Wang, Anthony , Dorfer, Christian , Feucht, Martha , Czech, Thomas , Zhang, Jianguo , Hidalgo, Eveline Teresa , Wong‐Kisiel, Lily C. , Wang, Feng‐Peng, Yao, Yi , Guo, Qiang , Li, Shao‐Chun, Stienen, Martin Nikolaus , Baro, Valentina , Oluigbo, Chima , Pearl, Phillip L. , Fallah, Aria

Mayo Clinic

Epilepsia | June 24, 2023 | Volume: 65 | Issue: 1 | Pages: 46-56

10.1111/epi.17689 | PMID 37347512 Get It

AbstractObjectivesAlthough hemispheric surgeries are among the most effective procedures for drug‐resistant epilepsy (DRE) in the pediatric population, there is a large variability in seizure outcomes at the group level. A recently developed HOPS score provides individualized estimation of likelihood of seizure freedom to complement clinical judgement. The objective of this study was to develop a freely accessible online calculator that accurately predicts the probability of seizure freedom for any patient at 1‐, 2‐, and 5‐years post‐hemispherectomy.MethodsRetrospective data of all pediatric patients with DRE and seizure outcome data from the original Hemispherectomy Outcome Prediction Scale (HOPS) study were included. The primary outcome of interest was time‐to‐seizure recurrence. A multivariate Cox proportional‐hazards regression model was developed to predict the likelihood of post‐hemispheric surgery seizure freedom at three time points (1‐, 2‐ and 5‐ years) based on a combination of variables identified by clinical judgment and inferential statistics predictive of the primary outcome. The final model from this study was encoded in a publicly accessible online calculator on the International Network for Epilepsy Surgery and Treatment (iNEST) website (https://hops‐calculator.com/).ResultsThe selected variables for inclusion in the final model included the five original HOPS variables (age at seizure onset, etiologic substrate, seizure semiology, prior non‐hemispheric resective surgery, and contralateral fluorodeoxyglucose–positron emission tomography [FDG‐PET] hypometabolism) and three additional variables (age at surgery, history of infantile spasms, and magnetic resonance imaging [MRI] lesion). Predictors of shorter time‐to‐seizure recurrence included younger age at seizure onset, prior resective surgery, generalized seizure semiology, FDG‐PET hypometabolism contralateral to the side of surgery, contralateral MRI lesion, non‐lesional MRI, non‐stroke etiologies, and a history of infantile spasms. The area under the curve (AUC) of the final model was 73.0%.SignificanceOnline calculators are useful, cost‐free tools that can assist physicians in risk estimation and inform joint decision‐making processes with patients and families, potentially leading to greater satisfaction. Although the HOPS data was validated in the original analysis, the authors encourage external validation of this new calculator.
Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization
King, Sontoria D. , Veliginti, Swathi , Brouwers, Martijn C.G.J. , Ren, Zhewen , Zheng, Wei , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Shu, Xiao‐Ou , Arslan, Alan A. , Freeman, Laura E. Beane , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Haiman, Christopher A. , Visvanathan, Kala , White, Emily , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Giovannucci, Edward L. , Hackert, Thilo , Hassan, Manal M. , Kurtz, Robert C. , Lee, I‐Min , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wentzensen, Nicolas , Yu, Kai , Wolpin, Brian M. , Li, Donghui , Patel, Alpa V. , Peters, Ulrike , Ríboli, Elio , Zhong, Jun, Antwi, Samuel O. , Zhong, Jun , Setiawan, Veronica W , Beane Freeman, Laura E , Canzian, Federico , Du, Mengmeng , Gallinger, Steven , Giles, Graham G , Goodman, Phyllis J , Haiman, Christopher A , Kogevinas, Manolis , Kooperberg, Charles , Marchand, Loïc Le , Neale, Rachel E , Visvanathan, Kala , White, Emily , Albanes, Demetrius , Andreotti, Gabriella , Babic, Ana , Berndt, Sonja I , Brais, Lauren K , Brennan, Paul , Buring, Julie E , Chaffee, Kari G. , Bamlet, William R , Chanock, Stephen Jacob , Fuchs, Charles S , Gaziano, J Michael , Giovannucci, Edward L , Hackert, Thilo , Hassan, Manal M , Katzke, Verena , Kurtz, Robert C , Lee, I-Min , Malats, Nuria , Murphy, Neil , Oberg, Ann L , Orlow, Irene , Porta, Miquel , Real, Francisco X , Rothman, Nathaniel , Sesso, Howard D , Silverman, Debra T. , Thompson, Ian M , Wactawski-Wende, Jean , Wang, Xiaoliang , Wentzensen, Nicolas , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Yu, Kai , Wolpin, Brian M , Duell, Eric J , Li, Donghui , Hung, Rayjean J , Perdomo, Sandra , McCullough, Marjorie L , Freedman, Neal D , Patel, Alpa V , Peters, Ulrike , Riboli, Elio , Sund, Malin , Tjønneland, Anne , Zhong, Jun , Van Den Eeden, Stephen K , Kraft, Peter , Risch, Harvey A , Amundadottir, Laufey , Klein, Alison P , Stolzenberg-Solomon, Rachael , Antwi, Samuel O , Arslan, Alan A , Shu, Xiao-Ou , Zheng, Wei , Wilkens, Lynne R , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Albanes, Demetrius , Rabe, Kari G. , Bamlet, William R. , Malats, Núria , Murphy, Neil , Orlow, Irene , Real, Francisco X. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Hung, Rayjean J. , McCullough, Marjorie L. , Freedman, Neal D. , Sund, Malin , Tjønneland, Anne , Kraft, Peter , Risch, Harvey A. , Ámundadóttir, Laufey T. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 24, 2023 | Volume: 32 | Issue: 9 | Pages: 1265-1269

10.1158/1055-9965.epi-23-0453 | PMID 37351909 Get It

Abstract Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer. Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for pancreatic cancer. Methods: Data from genome-wide association studies (GWAS) within the Pancreatic Cancer Cohort Consortium (PanScan; cases n = 5,090, controls n = 8,733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n = 4,163, controls n = 3,792) were analyzed. We used data on 68 genetic variants with four different MR methods [inverse variance weighting (IVW), MR-Egger, simple median, and penalized weighted median] separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and pancreatic cancer risk, using logistic regression to calculate ORs and 95% confidence intervals (CI), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and pancreatic cancer risk in the PanScan or PanC4 samples [e.g., PanScan, IVW OR, 1.04; 95% confidence interval (CI), 0.88–1.22; MR-Egger OR, 0.89; 95% CI, 0.65–1.21; PanC4, IVW OR, 1.07; 95% CI, 0.90–1.27; MR-Egger OR, 0.93; 95% CI, 0.67–1.28]. None of the four MR methods indicated an association between genetically predicted NAFLD and pancreatic cancer risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with pancreatic cancer risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and pancreatic cancer might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and pancreatic cancer.